Liver Cirrhosis, Hepatic Encephalopathy
Conditions
Keywords
quality of life
Brief summary
The investigators wish to investigate how the Continuous Reaction Time (CRT) method can be used in the diagnosis and monitoring of covert hepatic encephalopathy (cHE)in patients with cirrhosis of the liver. The hypothesis is that the CRT method (duration 10-2 minutes) can serve as a tool in the diagnosis and monitoring of cHE and is an alternative to using the Portosystemic Encephalopathy Test (PSE)(duration 20-25 minutes).
Detailed description
Objective: The aim of this project is to investigate whether continuous reaction time measurements (CRT) are suitable as a screening and monitoring tool for covert hepatic encephalopathy (c/mHE). Method: Sub-protocol 1: As a part of this PhD protocol 100 healthy individuals and 50 with chronic disease (not liver cirrhosis) will be tested using the CRT and PSE tests. This is to determine the normal range for the PSE test in the Danish population. Sub-protocol 2: A total of 120 (aprox. 145 to adjust for drop outs) patients with liver cirrhosis from two Danish hospitals will be examined with both CRT and with the test that is the closest we get to a gold standard, namely portosystemic encephalopathy test (PSE). We wish to examine if the CRT test agrees with the PSE test, which may be to time consuming to perform in everyday clinical practice, and with quality of life scores (SF-36 and Sickness Impact Profile). The relationship between the CRT and PSE test and various blood tests and the Charlston co-morbidity score will also be examined. Sub-protocol 3: Forty-four of the 120 included patients will, regardless of CRT test result, be randomized to treatment with lactulose, rifaximin and branched chain amino acids (BCAA) or placebo lactulose, rifaximin and BCAA. This is to evaluate whether the CRT method is able to detect a response to treatment, and see if changes in psychometric tests (PSE and CRT) are in accordance with quality of life scores and predicts subsequent development of overt hepatic encephalopathy. Perspective: CRT method should, if it proves good enough, continue to be the Danish test of choice and hopefully be more widely used in our country. The validation of tests for the diagnosis of covert hepatic encephalopathy will give cirrhotic patients with covert hepatic encephalopathy and reduced quality of life the best opportunity to be diagnosed and offered appropriate treatment. If the CRT method is not able to identify a population that benefits from anti-encephalopathy treatment other screening and monitoring tests should be used.
Interventions
DRUGLactulose and rifaximin
3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
DIETARY_SUPPLEMENTBranched Chain amino acids
30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
OTHERPlacebo
Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
Sponsors
Region of Southern Denmark
Odense University Hospital
Esbjerg Hospital - University Hospital of Southern Denmark
Mette Munk Lauridsen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
For healthy volunteers: * Age\> 18 years * Written informed consent * Speak and understand Danish For patients: * Age \> 18 years * Liver cirrhosis confirmed by biopsy or appropriate clinic and biochemistry, and imaging. * Written informed consent * Speak and understand Danish
Exclusion criteria
(patients and control persons): * Clinical manifest hepatic encephalopathy * Consumption of psychoactive substances within 6 days of test * Organic brain disease (i.e. prior stroke, dementia) * Hypothyroidism * Renal failure (creatinine\> 150 mg / dL) * Hyponatremia (Na \<125 mmol / L) * Sepsis or bleeding within one week prior to testing. * Serious sleep disorders * Current treatment with lactulose, rifaximin or BCAA
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Continuous Reaction Time Method versus Portosystemic Encephalopathy Test | baseline and 3 months | The investigators are evaluating if the CRT and PSE test are in accordance at inclusion and after 3 months of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Continuous Reaction Time Method versus Quality of Life (QoL) | baseline and 3 months | The results from both CRT and PSE test will be compared to the out come of the SF-36 and the SIP (Sickness impact profile) QoL measurements. |
| Correlation between CRT test and PSE test at inclusion | at baseline | The investigators wish to evaluate the correlation between the CRT and the PSE test at base line. |
| Correlation between psychometric test results and quality of life af base line | at base line | The investigators wish to evaluate the correlation between the psychometric test results (CRT test result and PSE test result) and quality of life. The scientific question is which test correlates best to QoL. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Danish normal values for the PSE test | at base line | 100 normal Danish persons will be tested using the PSE test to establish the Danish norm. |
Countries
Denmark
Outcome results
None listed